VT3989
Refractory pleural and non-pleural mesothelioma; Advanced solid tumors with NF2 mutations
Phase 1/2Active
Key Facts
Indication
Refractory pleural and non-pleural mesothelioma; Advanced solid tumors with NF2 mutations
Phase
Phase 1/2
Status
Active
Company
About Vivace Therapeutics
Vivace Therapeutics is a private, clinical-stage biotechnology company pioneering novel small molecule inhibitors targeting the Hippo-YAP pathway for cancer treatment. Its lead candidate, VT3989, is in Phase 1/2 trials for refractory mesothelioma and other solid tumors, representing a first-in-class approach. The company is backed by a seasoned management team and prominent life science investors, positioning it to address a significant unmet need in oncology, particularly in cancers driven by NF2 mutations and YAP hyperactivity.
View full company profile